LG AI Research Supplies Cancer Diagnosis AI Model 'EXAONEPath' to NVIDIA

LG AI Research is accelerating innovation in the bio sector with its artificial intelligence (AI) model for cancer diagnosis, 'EXAONEPath'.

According to industry sources on May 19, LG AI Research's EXAONEPath model was recently registered on NVIDIA's medical imaging platform 'MONAI'. EXAONEPath, which LG AI Research released as open source in August last year, is a model specialized in processing histopathology images. Its key feature is the ability to reduce both time and cost by shortening the conventional genetic testing period, which could take up to two weeks.

An official from LG AI Research explained, "If AI can be used to understand and analyze histopathology images, it will be possible to predict genetic mutations and determine appropriate treatment methods and drug types without the traditional genetic testing step."

LG AI Research will introduce EXAONEPath for the first time at its own booth at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held in Chicago, United States, from May 30 to June 3. ASCO is considered one of the world's top three cancer conferences, alongside the American Association for Cancer Research (AACR) and the European Society for Medical Oncology (ESMO). This year's event is expected to attract more than 40,000 participants from around the world.

Since early last year, LG AI Research has been tackling challenges in the bio sector, including joint research on predictive AI technologies for diagnosing and treating Alzheimer's disease and cancer with the Jackson Laboratory (JAX), a leading nonprofit genomics research institution in the United States. Earlier this year, LG AI Research also signed a joint research agreement with Professor Baek Minkyoung of Seoul National University's Department of Biological Sciences to develop 'next-generation protein structure prediction AI'.